TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03362723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
Study: NCT00075634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study: NCT02763475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m2 iv daily on day -5 to -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NK cell infusion
Description: * First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~* Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 1x10\^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
Study: NCT02238314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Study: NCT04022681

Intervention type: OTHER
Intervention: BALLETS
Description: Cohort were not exposed to any intervention. There information will be analysed from database searches.
Study: NCT00297102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 mcg, once daily, oral administration in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT04108104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpress LP
Description: 3-month treatment
Study: NCT00075634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT04108104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpress LP
Description: 3-month treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpress LP
Description: 3-month treatment
Study: NCT02656199

Intervention type: PROCEDURE
Intervention: Diaphragm Ultrasound
Description: Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
Study: NCT01705756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Kineret
Description: Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
Study: NCT02992652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
Study: NCT00016107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01501825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5 channels Multiway deep Transcranial Magnetic Stimulator
Description: During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: five channels Multiway deep Transcranial Magnetic Stimulation
Description: During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)
Study: NCT01130870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Threshold
Description: Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 75% of sensory threshold - Amplitude
Description: Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 50% of sensory threshold - Amplitude
Description: Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
Study: NCT04591548

Intervention type: DIAGNOSTIC_TEST
Intervention: proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample
Description: All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample
Description: All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
Study: NCT02714777

Intervention type: DEVICE
Intervention: Autonomic nervous system activity
Description: Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
Study: NCT04265235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: see 'arm' section
Study: NCT01696500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Study: NCT03314636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: See in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: See in arm description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-CT
Description: See in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: See in arm description
Study: NCT01519557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAR-100A
Description: 15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00320255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Oral tablets administered once daily in 5-, 10-, or 20-mg dose
Study: NCT00452452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Study: NCT00075634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02777008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Study: NCT04033250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure
Description: Bowel preparation
Study: NCT02939053

Intervention type: DEVICE
Intervention: SOZO
Description: The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
Study: NCT04244383

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: interleukin IL-1beta and interleukin IL-18
Description: pro-inflammatory cytokines measured in the serum

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: interleukin IL-1beta and interleukin IL-18
Description: pro-inflammatory cytokines measured in the serum
Study: NCT01182376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronedarone
Description: Dronedarone will be prescribed by the patient's team according to established guidelines.
Study: NCT02777008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-543
Study: NCT01182376

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by the patient's team according to established guidelines.
Study: NCT01715571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viberect
Description: Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary.
Study: NCT03245866

Intervention type: OTHER
Intervention: Observational/ no intervention
Study: NCT01056315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT3938Y
Description: Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Overencapsulated tablets of placebo, 16 weeks treatment.
Study: NCT00320255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apixaban
Description: Oral tablets administered once daily in 5-, 10-, or 20-mg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Oral tablets administered once daily in 5-, 10-, or 20-mg dose
Study: NCT03065946

Intervention type: OTHER
Intervention: Early wakening
Description: By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
Study: NCT02845700

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perceptual Retraining Treatment
Description: Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham Neutral training
Description: Control condition using systematic presentation of diluted neutral-neutral odor pairs.
Study: NCT02565537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: WFG vs. WFO LASIK
Study: NCT00320255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets administered once daily
Study: NCT01242410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon ring (Arabin Cervical Pessary)
Description: Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
Study: NCT02100020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Referral to physical activity
Description: Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
Study: NCT01063491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bypass graft angiography
Study: NCT02645903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard general anesthesia
Description: Cases to whom applied alone standard general anesthesia were determined as Group 2
Study: NCT00609180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal (Trophic) Feeding
Description: Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal (Trophic) Feeding
Description: Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Feeding
Description: Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Full Feeding
Description: Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids and Antioxidant Supplements
Description: Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids and Antioxidant Supplements
Description: Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
Study: NCT02501317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Perineal Rehabilitation protocol
Description: Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kari Bo protocol
Description: Group exercises to pelvic floor rehabilitation
Study: NCT02198599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobility-enhancing-nursing intervention
Description: Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
Study: NCT00543296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.59 mg Fluocinolone Acetonide implant
Description: 0.59 mg Fluocinolone Acetonide implant
Study: NCT01986387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer-to-Peer Support Mentoring
Description: The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
Study: NCT00839462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol foam spray, new formulation
Description: 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexpanthenol foam spray, old formulation
Description: 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
Study: NCT04495556

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
Study: NCT04192968

Intervention type: OTHER
Intervention: Cortical auditory evoked potentials
Description: Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
Study: NCT03580902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT-Buprenorphine
Description: Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
Study: NCT04033250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure
Description: Bowel preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure
Description: Bowel preparation
Study: NCT00798863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video assisted submandibular sialadenectomy
Description: Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
Study: NCT03122548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Administered by IV infusion over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by IV infusion over 30 minutes.
Study: NCT03580902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Standard outpatient buprenorphine maintenance
Study: NCT02709044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Study: NCT00233714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER Sirolimus-Eluting Coronary Stent
Description: Single dose Sirolimus-Eluting coronary stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER Sirolimus-Eluting Coronary Stent
Description: Double-dose Sirolimus-Eluting coronary stent
Study: NCT03580902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Standard outpatient buprenorphine maintenance